Dyslipidemias  >>  Isentress (raltegravir)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT00887653: Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

Completed
3
20
US
raltegravir, Isentress
The Miriam Hospital, Tufts Medical Center, Merck Sharp & Dohme LLC
HIV, Hyperlipidemia, Hypertriglyceridemia, HIV Infections
06/12
04/14

Download Options